Latest Content

Phase 3 NEJM data show oveporexton improves wakefulness, reduces cataplexy, and boosts quality of life in narcolepsy type 1, with manageable adverse effects.

How postmodern ideas shape DSM and the biopsychosocial model—why psychiatry needs method-based, truth-seeking care beyond consensus and eclecticism.

Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.

Psychedelic psilocybin therapy shows year-long relief in treatment-resistant depression, with strong response rates and stable safety.

Learn why SSRIs impair sex and how bupropion, PDE5 inhibitors, buspirone, and newer agents can prevent or reverse antidepressant sexual side effects.

Catch up on psychiatry news from last week.

FDA boosts DT120 lysergide ODT after phase 3 shows lasting depression relief; psychedelic tablet also advances for anxiety and other brain disorders.

Experts unpack screening for sexual dysfunction in psychiatric care, menopause and meds impacts, and when flibanserin may help restore desire.

Learn how to spot and treat sexual dysfunction in psychiatric care—screen causes, manage SSRI effects, and choose libido-friendly medications.

Public health professional Shambrekia Wise and her daughter Sandy discuss the origins of their travel-themed book series and its relevance to clinicians treating diverse young patients.

Discuss depression care challenges, comorbidities, and new treatments—submit cases, research, or CME ideas for Psychiatric Times’ September 2026 series.

Review the developments in GLP-1s in 2026.

A target trial emulation of more than 1.5 million matched adults ties GLP-1 RA initiation to lower mortality and cardiovascular events in serious mental illness.